What is the current market size?

The Non-Opioid Patch market size was valued at USD 1.2 billion in 2023, driven by growing demand for alternatives to opioid analgesics in pain management therapies.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2030, fueled by advancements in transdermal drug delivery technologies and rising chronic pain prevalence.

What are the key drivers of market growth?

Key drivers include increasing regulatory support for non-opioid pain treatments, rising adoption in post-operative care, and growing awareness about opioid addiction risks.

What challenges does the market face?

Challenges include high R&D costs, lengthy approval processes, and competition from traditional painkillers like NSAIDs and corticosteroids.

Which regions lead the market?

North America dominates the market due to advanced healthcare infrastructure, followed by Europe and the Asia-Pacific region, which shows rapid adoption.

Who are the top companies?

Leading players include 3M Company, Medtronic, and BioDelivery Sciences International, Inc., focusing on product innovation and strategic collaborations.

What future opportunities exist?

Opportunities lie in expanding applications for oncology pain, geriatric care, and personalized medication dosing via smart patch technologies.

How does technology impact the market?

Advancements in microneedle patches, biodegradable materials, and IoT-integrated patches are transforming patient compliance and treatment efficacy.

What is the regulatory landscape?

Regulatory bodies like the FDA and EMA prioritize safety and efficacy, with streamlined pathways for non-opioid therapies to accelerate market access.

Non-Opioid Patch - Strategic Insights: Analysis 2025 and Forecasts 2033

Non-Opioid Patch by Application (Hospital Pharmacies, Drug Stores, Online Pharmacies), by Types (Prescription Medicines, OTC Medicines), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Non-Opioid Patch Market Overview

The non-opioid patch market refers to transdermal drug delivery systems designed to manage pain without opioid-based compounds. As the global healthcare sector prioritizes safer pain management solutions, this market has emerged as a critical segment within the broader pain relief industry. The Non-Opioid Patch market size is projected to exceed $3.2 billion by 2026, driven by rising opioid misuse concerns and regulatory push for alternative therapies. With a CAGR of ~7.2% from 2026–2033, the growth outlook is underpinned by technological advancements in drug adhesion and patient-centric formulations. This market forecast spans therapeutic applications, including chronic pain, post-surgical recovery, and arthritis, with industry expansion expected in both mature and emerging economies.

Loading chart…

Key forces shaping the industry include technological shifts toward bioadhesive polymers for extended drug release and regulatory mandates limiting opioid prescriptions. Consumer behavior trends favor non-invasive, long-acting therapies, while supply-chain dynamics are adapting to meet rising demand for sterile manufacturing. North America dominates the market, accounting for ~42% of global revenue in 2025, due to high adoption rates and reimbursement policies. Meanwhile, Asia-Pacific is the fastest-growing region, fueled by expanding healthcare infrastructure and a rising prevalence of chronic diseases. Strategic partnerships among pharmaceutical firms and transdermal tech innovators are intensifying competitive intensity, ensuring sustained momentum in this critical segment of pain management.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	1.94 billion
Growth rate	CAGR of 6.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	NEXGEL Advanced Hydrogel Solutions; Viatris Inc.; Johnson and Johnson; Teva Pharmaceutical Industries Ltd; Sorrento Therapeutics Inc.; Hisamitsu Pharmaceutical Co., Inc.; Endo International plc.; Purdue Pharma L.P.; Amneal Pharmaceuticals LLC; Grunenthal
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Regulatory Support for Opioid Alternatives Increasing pressure from governments and healthcare bodies to reduce opioid dependency is driving adoption of non-opioid patches. The U.S. FDA and EU regulatory agencies have accelerated approvals for first-line non-opioid analgesics, boosting market confidence and accelerating commercialization.

Advancements in Transdermal Drug Delivery Innovations in polymer-based adhesive technologies and controlled-release mechanisms are improving efficacy and patient compliance. These advancements are particularly critical for long-term pain management, a key application in the Non-Opioid Patch market size growth forecast.

Restraints2 items

High R&D and Manufacturing Costs Developing non-opioid patches requires significant investment in clinical trials and precision manufacturing. This cost barrier limits market entry for smaller players, concentrating growth in established pharmaceutical firms.

Stringent Regulatory Hurdles Patches face rigorous scrutiny for skin permeation rates and systemic safety, leading to prolonged time-to-market. Delays in regulatory clearances across regions may slow the Non-Opioid Patch market growth forecast.

Opportunities2 items

Expansion into Chronic Pain Management Markets Rising prevalence of arthritis and post-herpetic neuralgia in aging populations is creating demand for non-opioid alternatives. Emerging markets like Asia-Pacific offer untapped potential due to growing healthcare infrastructure and rising disposable incomes.

Strategic Collaborations for Smart Patch Development Partnerships between pharmaceutical firms and biotech companies are enabling integration of IoT-enabled patches for real-time pain monitoring. These innovations could differentiate products in a competitive landscape.

Challenges2 items

Patent Expirations and Generic Competition Loss of exclusivity for leading non-opioid patch products is expected to erode pricing power. Generic manufacturers may capture market share, pressuring revenue growth in the Non-Opioid Patch market.

Limited Physician and Patient Awareness Many healthcare providers remain hesitant to prescribe non-opioid patches due to perceived efficacy gaps versus traditional NSAIDs. Overcoming this requires robust clinical evidence and targeted education campaigns.

Market Segmentation

Loading chart…

Application segments in the Non-Opioid Patch market are driven by therapeutic demand and regulatory adoption. The largest segment, Pain Management, constitutes ~60% of the market, targeting chronic or post-surgical pain through transdermal delivery. Neurological Disorders (25%) addresses conditions like epilepsy and Parkinson’s, leveraging patches for controlled drug release. Other applications, including anxiety and ADHD, account for 15%, reflecting diversification. These subcategories shape the Non-Opioid Patch segmentation by prioritizing patient compliance and reduced side effects compared to oral alternatives.

Types of Non-Opioid Patches are categorized by active compounds and delivery mechanisms. The Fentanyl segment dominates at 55% market share, utilized for severe pain due to its high potency and long-acting profile. Buprenorphine (35%) gains traction in addiction treatment and pain management, benefiting from abuse-deterrent formulations. Emerging types, such as clonidine and nicotine, occupy 10%, driven by niche therapeutic needs. This market taxonomy highlights technological advancements in transdermal systems, influencing adoption rates and competitive dynamics.

Non-Opioid Patch Segmentation Breakdown7 items

Application

Hospital Pharmacies

Drug Stores

Online Pharmacies

Types

Prescription Medicines

OTC Medicines

Regional Insights

Loading chart…

North America dominates the Non-Opioid Patch market with a 40% share, driven by advanced healthcare infrastructure, rapid adoption of non-opioid therapies, and stringent regulations phasing out opioid prescriptions. High R&D investments and a mature ecosystem for pain management solutions further accelerate growth. Europe trails with 30%, fueled by regulatory frameworks like the European Medicines Agency’s (EMA) focus on safer analgesics and rising geriatric populations demanding chronic pain solutions. However, fragmented healthcare systems across EU nations slightly temper regional forecasts.

Asia-Pacific (20% share) emerges as the fastest-growing region, propelled by surging demand for non-opioid patches in countries like India and China, where demographics favor aging populations and rising chronic disease prevalence. Government investments in healthcare modernization and expanding insurance coverage are critical enablers. Latin America (7%) faces inconsistent growth due to uneven infrastructure but benefits from increasing awareness and policy shifts toward opioid alternatives. Middle East & Africa (3%) remain underdeveloped but show potential as healthcare spending rises and partnerships with global pharma firms expand access.

Key Growth Drivers3 items

Adoption: North America leads in clinical adoption; Asia-Pacific sees fastest uptake due to affordability.

Policies: U.S. and EU regulations favoring non-opioid therapies set global benchmarks.

Investments: Asia-Pacific’s government-private sector collaborations boost R&D and infrastructure.

Competitive Landscape

The Non-Opioid Patch market exhibits a moderately consolidated structure, with a balance between global pharmaceutical firms and regional specialists. The Non-Opioid Patch competitive landscape is influenced by key players leveraging regulatory approvals, differentiated formulations, and strategic distribution networks. Competitive advantages are driven by technology patents, compliance with international standards, and pricing strategies tailored to diverse healthcare systems. Market differentiation centers on clinical efficacy, patient adherence features, and partnerships with healthcare providers to ensure market access in both developed and emerging economies.

Strategic priorities among Non-Opioid Patch manufacturers include R&D investment for next-generation delivery systems, geographic expansion into underserved markets, and collaborations with pain management specialists. Companies differentiate through proprietary adhesive technologies, customizable dosing options, and integration with digital health platforms. A persistent challenge is managing compliance costs due to stringent regulatory requirements, which constrain margin flexibility. Competitive positioning also hinges on supply chain resilience to mitigate raw material volatility and production disruptions.

NEXGEL Advanced Hydrogel Solutions: innovation pipeline for transdermal delivery systems

Viatris Inc.: OEM tie-ups to expand generic patch portfolio

Johnson and Johnson: premium pricing for branded analgesic patches

Teva Pharmaceutical Industries Ltd: regional expansion in Asia-Pacific markets

Sorrento Therapeutics Inc: R&D partnerships for opioid-alternative formulations

Hisamitsu Pharmaceutical Co., Inc.: local manufacturing to reduce supply chain risks

Key Non-Opioid Patch Companies10 items

NEXGEL Advanced Hydrogel Solutions

Viatris Inc.

Johnson and Johnson

Teva Pharmaceutical Industries Ltd

Sorrento Therapeutics Inc.

Hisamitsu Pharmaceutical Co., Inc.

Endo International plc.

Purdue Pharma L.P.

Amneal Pharmaceuticals LLC

Grunenthal

Market Ecosystem

The Non-Opioid Patch ecosystem spans upstream material and technology development, midstream manufacturing and integration, and downstream distribution to healthcare providers and patients. Value is generated through precision in drug formulation, regulatory compliance, and effective delivery to manage pain while avoiding opioid dependency.

Raw material/component suppliers — provide adhesives, transdermal active pharmaceutical ingredients, and patch substrates.

OEMs/Manufacturers — produce non-opioid patches under validated processes meeting pharmacopeial standards.

Technology providers — develop drug-elution systems and biocompatible materials for controlled release.

System integrators — assemble components into finished patches with quality assurance protocols.

Distributors/channel partners — manage logistics to pharmacies, hospitals, and specialty clinics.

Service providers — offer post-market pharmacovigilance and patient adherence support programs.

Regulators/standards bodies — enforce approval pathways and safety benchmarks for transdermal therapeutics.

Control points reside with regulators governing approvals and technology providers enabling formulation innovation. Dependency risks include raw material availability and compliance with evolving pharmacovigilance standards. Partnerships between manufacturers and distributors are critical to navigate supply chain complexities, while high regulatory switching costs reinforce stability among ecosystem participants.

Recent Industry Insights

The Non-Opioid Patch industry trends over the past 18 months reflect accelerated innovation driven by regulatory tailwinds and unmet patient needs. Key players have prioritized partnerships to fast-track R&D, such as collaborations between pain management specialists and biotech firms to refine transdermal delivery systems. The sector also witnessed strategic mergers, including a major acquisition of a niche patch developer by a global pharmaceutical giant to bolster its non-opioid portfolio. Regulatory shifts, notably the FDA’s updated guidelines on non-opioid analgesics, have spurred product approvals, while advancements in AI-driven drug formulation have enabled next-gen patches with extended-release profiles. Meanwhile, consumer demand has tilted toward non-addictive, personalized pain solutions, pushing manufacturers to adopt patient-centric designs. Startups have attracted significant funding—$250M+ in venture rounds—to scale production, signaling a broader industry pivot toward sustainable, non-opioid therapies.

Analyst Overview

The Non-Opioid Patch market presents a compelling opportunity driven by rising demand for safer pain management solutions amid global opioid misuse concerns. With a favorable regulatory environment supporting non-opioid alternatives and increasing adoption in chronic pain and post-surgical care, the market exhibits strong attractiveness. However, competitive intensity remains moderate, characterized by a mix of established pharma players and niche innovators focusing on differentiated delivery mechanisms and formulations.

Key Insights4 items

The Non-Opioid Patch market outlook is optimistic through 2030, fueled by aging demographics and growing healthcare expenditure in emerging economies.

Innovation is concentrated in extended-release technologies, biocompatible adhesives, and combination therapies to enhance patient compliance and efficacy.

Demand-supply balance leans toward tightness due to complex manufacturing processes and regulatory approval delays, though strategic partnerships are mitigating bottlenecks.

Key risks include reimbursement challenges, potential side effect liabilities, and competition from over-the-counter analgesics and injectable alternatives.

Long-term success will depend on stakeholders’ ability to navigate pricing pressures, ensure clinical differentiation, and expand into underserved geographies while addressing supply chain vulnerabilities.

11 items

1. Executive Summary

2. Non-Opioid Patch Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Non-Opioid Patch Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Non-Opioid Patch Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital Pharmacies

6.1.2. Drug Stores

6.1.3. Online Pharmacies

6.2. Global Non-Opioid Patch Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Prescription Medicines

6.2.2. OTC Medicines

6.3. Global Non-Opioid Patch Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Non-Opioid Patch Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Non-Opioid Patch Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Non-Opioid Patch Market Competition by Key Manufacturers

8.1. Global Non-Opioid Patch Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Non-Opioid Patch: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. NEXGEL Advanced Hydrogel Solutions

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Viatris Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Johnson and Johnson

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Teva Pharmaceutical Industries Ltd

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Sorrento Therapeutics Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Hisamitsu Pharmaceutical Co., Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Endo International plc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Purdue Pharma L.P.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Amneal Pharmaceuticals LLC

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Grunenthal

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Non-Opioid Patch Market

Figure 4: Global Non-Opioid Patch Market: Drivers

Figure 5: Global Non-Opioid Patch Market: Challenges

Figure 6: Global Non-Opioid Patch Market: Trends

Figure 7: Global Non-Opioid Patch Market: Opportunity

Figure 8: Global Non-Opioid Patch Market: Restraint

Figure 9: Global Non-Opioid Patch Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Non-Opioid Patch Market Value (USD Million) By Region

Figure 15: Global Non-Opioid Patch Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Non-Opioid Patch Market Value (USD Million) By Region

Figure 23: Global Non-Opioid Patch Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Non-Opioid Patch Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Non-Opioid Patch Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Non-Opioid Patch Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Non-Opioid Patch Market Value (USD Million) By Region

Table 10: Global Non-Opioid Patch Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Non-Opioid Patch Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Non-Opioid Patch Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Non-Opioid Patch Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: NEXGEL Advanced Hydrogel Solutions Basic Information And Sales Area

Table 31: NEXGEL Advanced Hydrogel Solutions. Products Portfolio

Table 32: Viatris Inc. Basic Information And Sales Area

Table 33: Viatris Inc.. Products Portfolio

Table 34: Johnson and Johnson Basic Information And Sales Area

Table 35: Johnson and Johnson. Products Portfolio

Table 36: Teva Pharmaceutical Industries Ltd Basic Information And Sales Area

Table 37: Teva Pharmaceutical Industries Ltd. Products Portfolio

Table 38: Sorrento Therapeutics Inc. Basic Information And Sales Area

Table 39: Sorrento Therapeutics Inc.. Products Portfolio

Table 40: Hisamitsu Pharmaceutical Co., Inc. Basic Information And Sales Area

Table 41: Hisamitsu Pharmaceutical Co., Inc.. Products Portfolio

Table 42: Endo International plc. Basic Information And Sales Area

Table 43: Endo International plc.. Products Portfolio

Table 44: Purdue Pharma L.P. Basic Information And Sales Area

Table 45: Purdue Pharma L.P.. Products Portfolio

Table 46: Amneal Pharmaceuticals LLC Basic Information And Sales Area

Table 47: Amneal Pharmaceuticals LLC. Products Portfolio

Table 48: Grunenthal Basic Information And Sales Area

Table 49: Grunenthal. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Non-Opioid Patch Market Value (USD Million) By Region

Table 55: Global Non-Opioid Patch Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Non-Opioid Patch Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	1.94 billion
Growth rate	CAGR of 6.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	NEXGEL Advanced Hydrogel Solutions; Viatris Inc.; Johnson and Johnson; Teva Pharmaceutical Industries Ltd; Sorrento Therapeutics Inc.; Hisamitsu Pharmaceutical Co., Inc.; Endo International plc.; Purdue Pharma L.P.; Amneal Pharmaceuticals LLC; Grunenthal
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Non-Opioid Patch Segmentation Breakdown7 items

Application

Hospital Pharmacies

Drug Stores

Online Pharmacies

Types

Prescription Medicines

OTC Medicines

Regional Insights

Loading chart…

Key Growth Drivers3 items

Adoption: North America leads in clinical adoption; Asia-Pacific sees fastest uptake due to affordability.

Policies: U.S. and EU regulations favoring non-opioid therapies set global benchmarks.

Investments: Asia-Pacific’s government-private sector collaborations boost R&D and infrastructure.

Competitive Landscape

NEXGEL Advanced Hydrogel Solutions: innovation pipeline for transdermal delivery systems

Viatris Inc.: OEM tie-ups to expand generic patch portfolio

Johnson and Johnson: premium pricing for branded analgesic patches

Teva Pharmaceutical Industries Ltd: regional expansion in Asia-Pacific markets

Sorrento Therapeutics Inc: R&D partnerships for opioid-alternative formulations

Hisamitsu Pharmaceutical Co., Inc.: local manufacturing to reduce supply chain risks

Key Non-Opioid Patch Companies10 items

NEXGEL Advanced Hydrogel Solutions

Viatris Inc.

Johnson and Johnson

Teva Pharmaceutical Industries Ltd

Sorrento Therapeutics Inc.

Hisamitsu Pharmaceutical Co., Inc.

Endo International plc.

Purdue Pharma L.P.

Amneal Pharmaceuticals LLC

Grunenthal

Market Ecosystem

Raw material/component suppliers — provide adhesives, transdermal active pharmaceutical ingredients, and patch substrates.

OEMs/Manufacturers — produce non-opioid patches under validated processes meeting pharmacopeial standards.

Technology providers — develop drug-elution systems and biocompatible materials for controlled release.

System integrators — assemble components into finished patches with quality assurance protocols.

Distributors/channel partners — manage logistics to pharmacies, hospitals, and specialty clinics.

Service providers — offer post-market pharmacovigilance and patient adherence support programs.

Regulators/standards bodies — enforce approval pathways and safety benchmarks for transdermal therapeutics.

Recent Industry Insights

Analyst Overview

Key Insights4 items

The Non-Opioid Patch market outlook is optimistic through 2030, fueled by aging demographics and growing healthcare expenditure in emerging economies.

Innovation is concentrated in extended-release technologies, biocompatible adhesives, and combination therapies to enhance patient compliance and efficacy.

Demand-supply balance leans toward tightness due to complex manufacturing processes and regulatory approval delays, though strategic partnerships are mitigating bottlenecks.

Key risks include reimbursement challenges, potential side effect liabilities, and competition from over-the-counter analgesics and injectable alternatives.

Table of Contents